| Year |
Citation |
Score |
| 2024 |
Ruminski PG, Rettig MP, DiPersio JF. Development of VLA4 and CXCR4 Antagonists for the Mobilization of Hematopoietic Stem and Progenitor Cells. Biomolecules. 14. PMID 39199390 DOI: 10.3390/biom14081003 |
0.324 |
|
| 2024 |
Ghobadi A, Aldoss I, Maude S, Bhojwani D, Wayne A, Bajel A, Dholaria B, Faramand R, Mattison R, Rijneveld A, Zwaan C, Calkoen F, Baruchel A, Boissel N, Rettig M, et al. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. Research Square. PMID 39149468 DOI: 10.21203/rs.3.rs-4676375/v1 |
0.307 |
|
| 2024 |
Li C, Anderson AK, Ruminski PG, Rettig MP, Karpova D, Kiem HP, DiPersio JF, Lieber A. A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model. Blood Advances. PMID 38843380 DOI: 10.1182/bloodadvances.2024012757 |
0.346 |
|
| 2024 |
Eissenberg LG, Ritchey JK, Rettig MP, Patel DA, Vij K, Gao F, Smith V, Han TH, DiPersio JF. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager. Plos One. 19: e0300174. PMID 38696390 DOI: 10.1371/journal.pone.0300174 |
0.35 |
|
| 2023 |
Ghobadi A, Foley NC, Cohen J, Rettig MP, Cashen AF, Gehrs LN, Christ S, Street E, Wallace N, Ritchey JK, Mehta-Shah N, Westervelt P, Fehniger TA, Kahl BS, Bartlett NL, et al. Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Advances. PMID 37871306 DOI: 10.1182/bloodadvances.2023011130 |
0.34 |
|
| 2023 |
Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O' Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, Turk R, Lee BH, Cooper ML, DiPersio JF. An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies. Leukemia. PMID 37798328 DOI: 10.1038/s41375-023-02039-z |
0.309 |
|
| 2023 |
Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski SM, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL. Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Advances. PMID 37327120 DOI: 10.1182/bloodadvances.2023010407 |
0.4 |
|
| 2023 |
Crees ZD, Rettig MP, DiPersio JF. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Therapeutic Advances in Hematology. 14: 20406207231174304. PMID 37250913 DOI: 10.1177/20406207231174304 |
0.369 |
|
| 2021 |
Ferraro F, Miller CA, Christensen KA, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Kohlschmidt J, Eisfeld AK, Bloomfield CD, Ramakrishnan SM, Day RB, Wartman LD, Uy GL, Welch JS, ... ... Rettig MP, et al. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34845035 DOI: 10.1073/pnas.2116427118 |
0.322 |
|
| 2021 |
Persaud SP, Ritchey JK, Kim S, Lim S, Ruminski PG, Cooper ML, Rettig MP, Choi J, DiPersio JF. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. The Journal of Clinical Investigation. PMID 34730109 DOI: 10.1172/JCI145501 |
0.326 |
|
| 2021 |
Xiang J, Shi M, Fiala MA, Gao F, Rettig MP, Uy GL, Schroeder MA, Weilbaecher KN, Stockerl-Goldstein K, Mollah S, DiPersio JF. Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Advances. PMID 34555850 DOI: 10.1182/bloodadvances.2021005149 |
0.324 |
|
| 2020 |
Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Frontiers in Oncology. 10: 1672. PMID 33014834 DOI: 10.3389/Fonc.2020.01672 |
0.343 |
|
| 2020 |
Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet K, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis LC, Topp MS, ... ... Rettig MP, et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. Blood. PMID 32929488 DOI: 10.1182/Blood.2020007732 |
0.338 |
|
| 2020 |
Oza A, Rettig MP, Powell P, O'Brien K, Clifford DB, Ritchey J, Gehrs L, Hollaway J, Major E, Fehniger TA, Miller CA, Soon-Shiong P, Rock A, DiPersio JF. Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. Blood Advances. 4: 2387-2391. PMID 32484854 DOI: 10.1182/Bloodadvances.2019000664 |
0.372 |
|
| 2020 |
Fontana F, Scott MJ, Allen JS, Cui G, Yang X, O'Neal J, Fletcher S, Yanaba N, Schmieder AH, Rettig MP, Ritchey J, Fiala MA, Vij R, Lanza GM. Abstract 1737: Nanotherapeutic targeting of drug resistant multiple myeloma cells through VLA4-contact facilitated drug-delivery of camptothecin prodrug Cancer Research. 80: 1737-1737. DOI: 10.1158/1538-7445.Am2020-1737 |
0.319 |
|
| 2020 |
Persaud SP, Cooper ML, Ritchey JK, Rettig MP, DiPersio JF. Antibody-Drug Conjugates Targeting CD45 Plus Janus Kinase (JAK) Inhibitors As Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 26: S150-S151. DOI: 10.1016/J.Bbmt.2019.12.701 |
0.466 |
|
| 2019 |
Karpova D, Rettig MP, DiPersio JF. Mobilized peripheral blood: an updated perspective. F1000research. 8. PMID 32025285 DOI: 10.12688/F1000Research.21129.1 |
0.35 |
|
| 2019 |
Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, Westervelt P, Vij R, DiPersio JF. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. PMID 31358485 DOI: 10.1016/J.Clml.2019.04.017 |
0.379 |
|
| 2019 |
Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, et al. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. The Journal of Clinical Investigation. 130. PMID 31085833 DOI: 10.1172/Jci124738 |
0.424 |
|
| 2019 |
Wang T, Sun H, Cui Zhou D, Liu R, Yao L, Fiala MA, Kohnen DR, O'Neal J, Rettig MP, Fowles JS, Oh ST, Jayasinghe RG, Vij R, DiPersio JF, Ding L. Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages Blood. 134: 364-364. DOI: 10.1182/Blood-2019-131361 |
0.314 |
|
| 2019 |
Jayasinghe RG, Wu Y, Zhu Y, Liu R, Fiala MA, Kohnen DR, Tsai C, Mani S, King J, Rettig MP, O'Neal J, Wang T, Foltz SM, Yao L, Sun H, et al. Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma Blood. 134: 5531-5531. DOI: 10.1182/Blood-2019-131005 |
0.426 |
|
| 2019 |
Cancilla D, Thakellapalli H, Meyers MJ, Rettig MP, Chendamarai E, Christ S, Karpova D, Ruminski PG, Ritchey JK, Morrow DM, Prinsen M, DiPersio JF. Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization Blood. 134: 1916-1916. DOI: 10.1182/Blood-2019-124373 |
0.474 |
|
| 2019 |
Persaud SP, Cooper ML, Ritchey JK, Rettig MP, DiPersio JF. CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease Blood. 134: 3200-3200. DOI: 10.1182/Blood-2019-123519 |
0.474 |
|
| 2019 |
Uy GL, Aldoss I, Foster MC, Sallman DA, Sweet KL, Rizzieri DA, Sayre PH, Advani AS, Emadi A, Wieduwilt MJ, Vey N, Ciceri F, Carrabba MG, Moyo T, Church SE, ... Rettig MP, et al. Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients Blood. 134: 733-733. DOI: 10.1182/Blood-2019-122073 |
0.324 |
|
| 2019 |
Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Schmitz M, Liang Y, Cesano A, ... ... Rettig MP, et al. Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia Blood. 134: 460-460. DOI: 10.1182/Blood-2019-121870 |
0.309 |
|
| 2019 |
DiPersio JF, Rettig M, Persaud S. DARTS, Bites and ADCs for the Treatment of AML and for Conditioning for Allogeneic Stem Cell Transplantation Clinical Lymphoma Myeloma and Leukemia. 19: S86. DOI: 10.1016/J.Clml.2019.07.429 |
0.372 |
|
| 2018 |
Rettig MP, DiPersio JF. CiTE antibody for AML. Blood. 132: 2425-2427. PMID 30523124 DOI: 10.1182/Blood-2018-10-879668 |
0.336 |
|
| 2018 |
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. The New England Journal of Medicine. PMID 30380364 DOI: 10.1056/Nejmoa1808777 |
0.369 |
|
| 2018 |
Rettig MP. Get Outta Here! Addition of Mobilizing Agents to Conditioning Regimen Improves Donor Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Wiskott-Aldrich Syndrome. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29753160 DOI: 10.1016/J.Bbmt.2018.05.003 |
0.379 |
|
| 2018 |
Buatois V, Johnson Z, Salgado-Pires S, Papaïoannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, ... ... Rettig M, et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia. Molecular Cancer Therapeutics. PMID 29743205 DOI: 10.1158/1535-7163.Mct-17-1095 |
0.396 |
|
| 2018 |
Ghobadi A, Rettig MP, Holt MS, Ritchey JK, Kennerly K, Chendamarai E, Eissenberg L, DiPersio JF. Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice. Blood. PMID 29695518 DOI: 10.1182/Blood-2017-10-811620 |
0.427 |
|
| 2018 |
Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, Rettig MP, Wang B, Eissenberg LG, Ghobadi A, Gehrs LN, Prior JL, Achilefu S, Miller CA, Fronick CC, et al. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. PMID 29483708 DOI: 10.1038/s41375-018-0065-5 |
0.362 |
|
| 2018 |
Kotagiri N, Cooper ML, Rettig M, Egbulefu C, Prior J, Cui G, Karmakar P, Zhou M, Yang X, Sudlow G, Marsala L, Chanswangphuwana C, Lu L, Habimana-Griffin L, Shokeen M, et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. Nature Communications. 9: 275. PMID 29348537 DOI: 10.1038/S41467-017-02758-9 |
0.334 |
|
| 2018 |
Eissenberg LG, Ritchey J, Rettig MP, Fox JA, Guenot J, DiPersio JF. AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia Blood. 132: 2727-2727. DOI: 10.1182/Blood-2018-99-118573 |
0.461 |
|
| 2018 |
Uy GL, Rettig MP, Vey N, Godwin J, Foster MC, Rizzieri DA, Arellano ML, Topp MS, Huls G, Jongen-Lavrencic M, Martinelli G, Paolini S, Ciceri F, Carrabba MG, Sweet KL, et al. Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Blood. 132: 764-764. DOI: 10.1182/Blood-2018-99-117085 |
0.366 |
|
| 2018 |
Persaud SP, Cooper ML, Rettig MP, DiPersio JF. Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers Blood. 132: 2035-2035. DOI: 10.1182/Blood-2018-99-116894 |
0.463 |
|
| 2018 |
Jacobs K, Viero C, Godwin J, Baughman J, Sun J, Ying K, Muth J, Hong S, Vey N, Sweet KL, Uy GL, Ravandi F, Foster MC, Rizzieri DA, Arellano ML, ... Rettig MP, et al. Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy Blood. 132: 2738-2738. DOI: 10.1182/Blood-2018-99-112615 |
0.345 |
|
| 2018 |
Rettig MP, Uy GL, Bashey A, Devine S, Jaglowski S, Vainstein A, Sorani E, Chen H, Bohana-Kashtan O, Shaw S, Westervelt P, DiPersio JF. Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product Blood. 132: 118-118. DOI: 10.1182/Blood-2018-99-109701 |
0.39 |
|
| 2017 |
Ghai A, Maji D, Rettig M, Chanswangphuwana C, DiPersio J, Akers W, Achilefu S, Dehdashti F, Vij R, Shokeen M. Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29025987 DOI: 10.2967/Jnumed.117.196063 |
0.404 |
|
| 2017 |
Cashen A, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28476490 DOI: 10.1016/J.Bbmt.2017.04.024 |
0.448 |
|
| 2017 |
Karpova D, Ritchey J, Holt M, Abou-Ezzi G, Monlish D, Batoon L, Millard S, Spohn G, Wiercinska E, Chendamarai E, Yang W, Christ S, Gehrs L, Schuettpelz LG, Dembowsky K, ... ... Rettig M, et al. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. Blood. PMID 28400375 DOI: 10.1182/Blood-2016-10-746909 |
0.396 |
|
| 2017 |
Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. PMID 28292947 DOI: 10.1182/Blood-2016-09-739722 |
0.448 |
|
| 2017 |
Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang S, Zhou J, Alatrash G, Ciurea SO, Rettig M, DiPersio JF, et al. Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate, in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28096272 DOI: 10.1158/1078-0432.Ccr-16-1904 |
0.416 |
|
| 2017 |
Uy GL, Rettig MP, Fletcher T, Riedell PA, Stockerl-Goldstein KE, Ghobadi A, Jacoby M, Cashen AF, Romee R, Pusic I, Abboud CN, Schroeder MA, Vij R, Westervelt P, DiPersio JF. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML Blood. 130: 816-816. DOI: 10.1182/Blood.V130.Suppl_1.816.816 |
0.393 |
|
| 2017 |
Uy GL, Godwin J, Rettig MP, Vey N, Foster M, Arellano ML, Rizzieri DA, Topp MS, Huls G, Lowenberg B, Martinelli G, Paolini S, Ciceri F, Carrabba MG, Ballesteros-Merino C, et al. Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood. 130: 637-637. DOI: 10.1182/Blood.V130.Suppl_1.637.637 |
0.387 |
|
| 2017 |
Jacobs K, Godwin J, Foster M, Vey N, Uy GL, Rizzieri DA, Arellano ML, Rettig MP, Christ S, Topp MS, Huls G, Lowenberg B, Martinelli G, Paolini S, Ciceri F, et al. Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy Blood. 130: 3856-3856. DOI: 10.1182/Blood.V130.Suppl_1.3856.3856 |
0.374 |
|
| 2017 |
Karpova D, Ritchey J, Holt M, Abou-Ezzi G, Monlish D, Schuettpelz L, Yang W, Pettit A, Rettig M, Boenig H, DiPersio J. Expansion and maintenance of hematopoietic stem and progenitor cells in course of long-term inhibition of CXCR4/CXCL12 signaling Experimental Hematology. 53: S92. DOI: 10.1016/J.Exphem.2017.06.213 |
0.332 |
|
| 2016 |
Kim AG, Vrecenak JD, Boelig MM, Eissenberg L, Rettig MP, Riley JS, Holt MS, Conner MA, Loukogeorgakis SP, Li H, DiPersio JF, Flake AW, Peranteau WH. Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by α4β1/7 inhibition. Blood. PMID 27650329 DOI: 10.1182/Blood-2016-06-723981 |
0.415 |
|
| 2016 |
Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R. Severe Cytokine Release Syndrome Following T-Cell Replete Peripheral Blood Haploidentical Donor Transplant is Associated with Poor Survival and Anti-IL-6 Therapy is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27318038 DOI: 10.1016/J.Bbmt.2016.06.010 |
0.369 |
|
| 2016 |
Karpova D, Rettig MP, Eissenberg L, Ritchey J, Holt M, Heier R, Arnett S, Meyers M, Griggs DW, Ruminski P, Morrow D, DiPersio JF. Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice Blood. 128: 659-659. DOI: 10.1182/Blood.V128.22.659.659 |
0.373 |
|
| 2016 |
Karpova D, Ritchey J, Holt M, Monlish D, Schuettpelz LG, Yang W, Levesque J, Pettit AR, Rettig MP, Bonig H, DiPersio JF. Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling Blood. 128: 2648-2648. DOI: 10.1182/blood.V128.22.2648.2648 |
0.349 |
|
| 2016 |
Chanswangphuwana C, Rettig MP, Akers W, Hathi D, Holt M, O'Neal J, Ritchey J, Kohnen D, King JA, Tomasson MH, Vij R, Shokeen M, DiPersio JF. Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors Blood. 128: 2056-2056. DOI: 10.1182/Blood.V128.22.2056.2056 |
0.449 |
|
| 2016 |
Schroeder MA, Rettig MP, Willey S, Fletcher T, Meier S, Wang T, Trinkaus K, Romee R, Ghobadi A, Pusic I, Abboud C, Stockerl-Goldstein K, Uy GL, Vij R, Westervelt P, et al. Phase I Study of Brentuximab Vedotin for the Prevention of Acute GvHD after Unrelated Allogeneic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 22: S413. DOI: 10.1016/J.Bbmt.2015.11.947 |
0.38 |
|
| 2015 |
Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, et al. [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1110-1122. PMID 28142024 DOI: 10.1038/mt.2015.48 |
0.333 |
|
| 2015 |
Al Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF. Targeting CD123 in AML using a T-cell directed dual-affinity re-targeting (DART®) platform. Blood. PMID 26531164 DOI: 10.1182/Blood-2014-05-575704 |
0.446 |
|
| 2015 |
Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, et al. [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1110-22. PMID 25807290 DOI: 10.1038/Mt.2015.48 |
0.439 |
|
| 2015 |
Abboud R, Keller J, Slade M, Rettig MP, Meier S, DiPersio JF, Fehniger TA, Trinkaus K, Uy GL, Westervelt P, Vij R, Abboud CN, Vu K, Bhamidipati PK, Romee R. T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy Blood. 126: 3106-3106. DOI: 10.1182/Blood.V126.23.3106.3106 |
0.369 |
|
| 2014 |
Ghobadi A, Rettig MP, Cooper ML, Holt MS, Ritchey JK, Eissenberg L, DiPersio JF. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. Blood. 124: 2752-4. PMID 25342668 DOI: 10.1182/Blood-2014-08-595967 |
0.411 |
|
| 2014 |
Eissenberg LG, Rettig M, Dehdashti F, Piwnica-Worms D, DiPersio JF. Suicide genes: Monitoring cells in patients with a safety switch Frontiers in Pharmacology. 5. DOI: 10.3389/Fphar.2014.00241 |
0.32 |
|
| 2014 |
Uy G, Stewart S, Baughman J, Rettig M, Chichili G, Bonvini E, Wigginton J, Lechleider R, DiPersio J. A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML) Journal For Immunotherapy of Cancer. 2: P87. DOI: 10.1186/2051-1426-2-S3-P87 |
0.456 |
|
| 2014 |
Manning PT, Capoccia BJ, Rettig MP, Hiebsch RR, Karr RW, DiPersio JF, Frazier WA. Dual-Function Anti-CD47mAbs Induce Tumor Cell Death and Promote Phagocytosis Resulting in Enhanced in Vivo Efficacy Blood. 124: 991-991. DOI: 10.1182/Blood.V124.21.991.991 |
0.434 |
|
| 2014 |
Campbell A, Chendamarai E, Holt M, Prior J, Eissenberg L, Rettig MP, Vuagniaux G, Zanna C, DiPersio JF. Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML Blood. 124: 5296-5296. DOI: 10.1182/Blood.V124.21.5296.5296 |
0.392 |
|
| 2014 |
Eissenberg LG, Rettig MP, Ritchey JK, Fulton R, Dehdashti F, Piwnica-Worms D, DiPersio JF. [18F]-Fhbg-PET/CT Imaging of CD34-TK75+ T Cells in Allogeneic HSCT Recipients after Donor Lymphocyte Infusion (IND#11917; Clinicaltrials.Gov Identifier: NCT00871702) Biology of Blood and Marrow Transplantation. 20: S129-S130. DOI: 10.1016/J.Bbmt.2013.12.197 |
0.358 |
|
| 2014 |
Schroeder MA, Merida S, Schwab D, Rettig MP, Meier S, Lopez S, Trinkaus K, Uy GL, Cashen A, Stockerl-Goldstein K, Westervelt P, DiPersio JF. Sargramostim (GM-CSF) Combined with IV Plerixafor to Mobilize Peripheral Blood Stem Cells (PBSC) from Normal HLA-Matched Allogeneic Sibling Donors Biology of Blood and Marrow Transplantation. 20: S42-S43. DOI: 10.1016/J.Bbmt.2013.12.036 |
0.41 |
|
| 2013 |
Macanas-Pirard P, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, Leisewitz F, Gidi V, Riquelme E, Montecinos VP, Swett P, Besa P, Ramirez P, Ocqueteau M, Kalergis AM, Holt M, ... Rettig M, et al. mENT1 inhibition by NBMPR chemoprotects APL cells from Ara-C and gemcitabine-induced cell death. Plos One. DOI: 10.1371/Journal.Pone.0037203.G008 |
0.347 |
|
| 2013 |
Rettig MP, Ghobadi A, Holt M, Meier S, Ritchey J, Tahirovic Y, Bridges A, Gooding D, Dipersio JF. ALT-1188: A New CXCR4 Antagonist In Development For Mobilization Of HSPCs Blood. 122: 891-891. DOI: 10.1182/Blood.V122.21.891.891 |
0.489 |
|
| 2013 |
AL Hussaini MH, Ritchey J, Rettig MP, Eissenberg L, Uy GL, Chichili G, Moore PA, Johnson S, Collins L, Bonvini E, DiPersio JF. Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs®) Blood. 122: 360-360. DOI: 10.1182/Blood.V122.21.360.360 |
0.452 |
|
| 2013 |
Rettig MP, Holt M, Prior J, Shacham S, Kauffman M, McCauley D, Dipersio JF. Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML) Blood. 122: 237-237. DOI: 10.1182/Blood.V122.21.237.237 |
0.464 |
|
| 2013 |
Uy GL, Rettig MP, McFarland K, DiPersio JF. Abstract LB-162: Targeting CXCR4 for treatment of relapsed or refractory AML. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-162 |
0.413 |
|
| 2012 |
Macanas-Pirard P, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, Leisewitz F, Gidi V, Riquelme E, Montecinos VP, Swett P, Besa P, Ramirez P, Ocqueteau M, Kalergis AM, Holt M, ... Rettig M, et al. Bone marrow stromal cells modulate mouse ent1 activity and protect leukemia cells from cytarabine induced apoptosis Plos One. 7. PMID 22629369 DOI: 10.1371/Journal.Pone.0037203 |
0.386 |
|
| 2012 |
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 119: 3917-24. PMID 22308295 DOI: 10.1182/Blood-2011-10-383406 |
0.344 |
|
| 2012 |
Xu M, Rettig MP, Sudlow G, Wang B, Akers WJ, Cao D, Mutch DG, DiPersio JF, Achilefu S. Preclinical evaluation of Mab CC188 for ovarian cancer imaging. International Journal of Cancer. Journal International Du Cancer. 131: 1351-9. PMID 22130973 DOI: 10.1002/Ijc.27380 |
0.339 |
|
| 2012 |
Juarez JG, Harun N, Thien M, Welschinger R, Baraz R, Pena AD, Pitson SM, Rettig M, DiPersio JF, Bradstock KF, Bendall LJ. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood. 119: 707-16. PMID 22049516 DOI: 10.1182/Blood-2011-04-348904 |
0.397 |
|
| 2012 |
Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 26: 34-53. PMID 21886173 DOI: 10.1038/Leu.2011.197 |
0.426 |
|
| 2012 |
Schroeder MA, Lopez S, Rettig MP, Trinkaus K, Westervelt P, DiPersio JF. High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability Blood. 120: 4095-4095. DOI: 10.1182/Blood.V120.21.4095.4095 |
0.452 |
|
| 2012 |
Cashen A, Rettig M, Gao F, Reineck T, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF in Lymphoma Patients Undergoing Autologous Stem Cell Collection Biology of Blood and Marrow Transplantation. 18: S205. DOI: 10.1182/Blood.V116.21.823.823 |
0.447 |
|
| 2012 |
Ramsingh G, Rettig M, Gabriel J, Westervelt P, Uy G, Abboud C, DiPersio J. Booster Infusion of T-Cell Depleted, CD34+ Enriched, Donor Cells Results in Sustained Count Recovery for Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 18: S345. DOI: 10.1016/J.Bbmt.2011.12.371 |
0.471 |
|
| 2012 |
Schroeder M, Rettig M, Uy G, Lopez S, Trinkhaus K, Graubert T, DiPersio J. Cxcl12 G801A Polymorphisms Do Not Predict Response to Mobilization by Plerixafor in Normal Allogeneic Stem Cell Donors Biology of Blood and Marrow Transplantation. 18: S261. DOI: 10.1016/J.Bbmt.2011.12.169 |
0.345 |
|
| 2012 |
Ansstas G, Mir F, Rettig MP, Schroeder M, Eissenberg L, DiPersio JF. Application of CXCR4 inhibitors in leukemia Novel Developments in Stem Cell Mobilization: Focus On Cxcr4. 335-349. DOI: 10.1007/978-1-4614-1960-0_17 |
0.325 |
|
| 2011 |
Schroeder MA, Rettig MP, Lopez S, Mir F, Trinkaus K, Uy GL, DiPersio JF. Outcomes of Patients Receiving Allogeneic Peripheral Blood Stem Cell Products Mobilized with Intravenous Plerixafor Blood. 118: 314-314. DOI: 10.1182/Blood.V118.21.314.314 |
0.434 |
|
| 2010 |
Cashen A, Rettig MP, Gao F, Abboud CN, Stockerl-Goldstein KE, Vij R, Uy GL, Westervelt P, DiPersio JF. Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection Blood. 116: 823-823. DOI: 10.1182/blood.v116.21.823.823 |
0.355 |
|
| 2010 |
Rettig MP, Lopez S, McFarland K, DiPersio JF. Rapid and Prolonged Mobilization of Human CD34+ Hematopoietic Stem Cells Following Intravenous (IV) Administration of Plerixafor Blood. 116: 2261-2261. DOI: 10.1182/Blood.V116.21.2261.2261 |
0.442 |
|
| 2009 |
Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, DiPersio JF. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 114: 1340-3. PMID 19571319 DOI: 10.1182/Blood-2008-10-184721 |
0.385 |
|
| 2009 |
Rettig MP, Ramirez P, Nervi B, DiPersio JF. CXCR4 and mobilization of hematopoietic precursors. Methods in Enzymology. 460: 57-90. PMID 19446720 DOI: 10.1016/S0076-6879(09)05203-3 |
0.409 |
|
| 2009 |
Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 113: 6206-14. PMID 19050309 DOI: 10.1182/Blood-2008-06-162123 |
0.459 |
|
| 2009 |
Uy GL, Rettig MP, McFarland K, Hladnik L, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein K, Vij R, Westervelt P, DiPersio JF. A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML. Blood. 114: 787-787. DOI: 10.1182/Blood.V114.22.787.787 |
0.351 |
|
| 2009 |
Rettig MP, McFarland K, Ritchey J, Holt M, Deych E, Lopez S, Gabriel J, Bauer SL, Cashen AF, DiPersio JF. Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor. Blood. 114: 32-32. DOI: 10.1182/Blood.V114.22.32.32 |
0.467 |
|
| 2008 |
Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opinion On Biological Therapy. 8: 1797-804. PMID 18847313 DOI: 10.1517/14712598.8.11.1797 |
0.422 |
|
| 2008 |
Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 1045-56. PMID 18721768 DOI: 10.1016/J.Bbmt.2008.07.004 |
0.46 |
|
| 2008 |
Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, Dipersio JF. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 112: 990-8. PMID 18426988 DOI: 10.1182/Blood-2007-12-130179 |
0.415 |
|
| 2008 |
Ramirez PA, Rettig M, Holt M, Ritchey J, DiPersio JF. Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF Blood. 112: 615-615. DOI: 10.1182/Blood.V112.11.615.615 |
0.434 |
|
| 2008 |
Rettig MP, Shannon WD, Ritchey J, Holt M, McFarland K, Lopez S, Gabriel J, DiPersio JF. Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor Blood. 112: 3476-3476. DOI: 10.1182/Blood.V112.11.3476.3476 |
0.461 |
|
| 2008 |
Uy GL, Rettig MP, McFarland KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein K, Vij R, Westervelt P, DiPersio JF. Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease. Blood. 112: 1944-1944. DOI: 10.1182/Blood.V112.11.1944.1944 |
0.424 |
|
| 2008 |
Ramirez P, Holt M, Rettig M, Ritchey J, DiPersio J. 3: Mobilization of Normal Mouse Progenitors and Acute Promyelocytic Leukemia (APL) Cells With Inhibitors of CXCR4 and VLA-4 in Splenectomized and Unsplenectomized Mice Biology of Blood and Marrow Transplantation. 14: 1-2. DOI: 10.1182/Blood.V110.11.2219.2219 |
0.45 |
|
| 2008 |
Ramirez P, Rettig M, Holt M, DiPersio J. 53: Rapamycin Partially Overcomes the in vitro Protective Effect of M2–10B4 Mesenchymal Stromal Cells (MSC) to Murine mCGPR/+ Acute Promyelocytic Leukemic (APL) Cells Against Chemotherapy Biology of Blood and Marrow Transplantation. 14: 22. DOI: 10.1016/J.Bbmt.2007.12.061 |
0.418 |
|
| 2007 |
Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, Bonyhadi ML, Berenson RJ, Prior JL, Piwnica-Worms D, Nolta JA, DiPersio JF. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Experimental Hematology. 35: 1823-38. PMID 17764813 DOI: 10.1016/J.Exphem.2007.06.007 |
0.392 |
|
| 2007 |
Uy GL, Rettig MP, Ramirez P, Nervi B, Abboud CN, DiPersio JF. Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100. Blood. 110: 867-867. DOI: 10.1182/Blood.V110.11.867.867 |
0.399 |
|
| 2007 |
Ramirez PA, Rettig MP, Holt M, DiPersio JF. M2-10B4 Mesenchymal Stromal Cells Confer an In Vitro Protective Effect of Murine mCGPR/+ Acute Promyelocytic Leukemic Cells Against Chemotherapy. Blood. 110: 2844-2844. DOI: 10.1182/Blood.V110.11.2844.2844 |
0.44 |
|
| 2007 |
Rettig MP, Ramirez P, Shannon WD, Uy GL, Lopez S, Ritchey JK, DiPersio JF. Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man. Blood. 110: 1203-1203. DOI: 10.1182/Blood.V110.11.1203.1203 |
0.441 |
|
| 2007 |
Rettig M, Nervi B, Ritchey J, Prior J, Piwnica-Worms D, Wang H, Bauer G, Walker J, Bonyhadi M, Berenson R, Nolta J, DiPersio J. 322: In vivo bioluminescence and [18F]-FHBG micropet imaging studies of human T cell trafficking, expansion, and xenogeneic graft-versus-host-disease following different routes of human T cell administration Biology of Blood and Marrow Transplantation. 13: 117. DOI: 10.1016/J.Bbmt.2006.12.327 |
0.35 |
|
| 2006 |
Nervi B, Ramirez P, Holt M, Rettig MP, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy. Blood. 108: 569-569. DOI: 10.1182/Blood.V108.11.569.569 |
0.459 |
|
| 2006 |
Schroeder MA, DiPersio JF, Rettig MP, Ritchey JK. Forced Expression of the “IY” Mutant Inosine Monophosphate Dehydrogenase II Results in Physiologically Significant Resistance to Mycophenolic Acid In Vitro. Blood. 108: 5480-5480. DOI: 10.1182/Blood.V108.11.5480.5480 |
0.431 |
|
| 2006 |
Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, Prior JL, Piwnica-Worms D, Nolta JA, DiPersio JF. In Vivo Bioluminescence Imaging (BLI) and Sequential 18F]FHBG microPET Imaging Studies of Human T Cell (huT) Trafficking, Expansion and Xenogeneic Graft-Versus-Host-Disease (XGVHD) Following Different Routes of T Cell Administration. Blood. 108: 5178-5178. DOI: 10.1182/Blood.V108.11.5178.5178 |
0.442 |
|
| 2006 |
Rettig MP, Ritchey JK, DiPersio JF. Allogeneic Recipients of Ex-Vivo Manipulated Donor T Cells Have Altered Plasma Analyte Profiles Compared to Recipients of Unmanipulated T Cells. Blood. 108: 3227-3227. DOI: 10.1182/Blood.V108.11.3227.3227 |
0.445 |
|
| 2006 |
Rettig M, Devine SM, Ritchey J, DiPersio JF. Phenotypic and Functional Analysis of T-Cells Mobilized in HLA-Matched Sibling Donors Following Treatment with the Chemokine Antagonist AMD3100. Blood. 108: 3001-3001. DOI: 10.1182/Blood.V108.11.3001.3001 |
0.462 |
|
| 2006 |
Bauer G, Walker J, Nervi B, Ritchey J, Rettig M, Hughes J, Eades B, Nolta J, DiPersio J. 1113. Large Scale Ex Vivo Expansion of Human T Cells under GMP Conditions Consistently Yields Fully Functional T Cells In Vivo Proven by Induction of Lethal GvHD in a Mouse Xenotransplant Model Molecular Therapy. 13: S428. DOI: 10.1016/J.Ymthe.2006.08.1219 |
0.437 |
|
| 2006 |
Rettig M, Ritchey J, Prior J, Piwnica-Worms D, Bonyhadi M, DiPersio J. Delayed GCV-mediated ablation of ΔCD34-tk transduced and selected murine T cells preserves GVL activity while mitigating GVHD Biology of Blood and Marrow Transplantation. 12: 65-66. DOI: 10.1016/J.Bbmt.2005.11.206 |
0.354 |
|
| 2006 |
Nervi B, Rettig M, Ritchey J, Wang H, Bauer G, Walker J, Bonyhadi M, Berenson R, Herrbrich P, Hess D, Nolta J, DiPersio J. Ex vivo activated and transduced human T cells generate lethal GVHD in a mouse model, and are efficiently eliminated in vivo with suicide gene therapy Biology of Blood and Marrow Transplantation. 12: 53. DOI: 10.1016/J.Bbmt.2005.11.167 |
0.331 |
|
| 2006 |
Nervi B, Holt M, Rettig M, Bridger G, Ley T, DiPersio J. In vivo bioluminescence imaging of acute promyelocytic leukemia cell trafficking and mobilization by AMD3100 Biology of Blood and Marrow Transplantation. 12: 18. DOI: 10.1016/J.Bbmt.2005.11.059 |
0.345 |
|
| 2005 |
Wandersee NJ, Punzalan RC, Rettig MP, Kennedy MD, Pajewski NM, Sabina RL, Paul Scott J, Low PS, Hillery CA. Erythrocyte adhesion is modified by alterations in cellular tonicity and volume. British Journal of Haematology. 131: 366-77. PMID 16225657 DOI: 10.1111/J.1365-2141.2005.05767.X |
0.658 |
|
| 2005 |
Rettig M, Ritchey J, Prior J, Piwnica-Worms D, Bonyhadi M, DiPersio J. Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT. Blood. 106: 5257-5257. DOI: 10.1182/Blood.V106.11.5257.5257 |
0.469 |
|
| 2005 |
Schroeder MA, Rettig MP, Ritchey JK, DiPersio JF. Inosine Monophosphate Dehydrogenase II Mutant (Thr-333-Ile + Ser-351-Tyr) Does Not Confer Resistance to Mycophenolic Acid In Vivo. Blood. 106: 5226-5226. DOI: 10.1182/Blood.V106.11.5226.5226 |
0.442 |
|
| 2005 |
Rettig M, Holt M, Liu F, Ritchey J, Link D, Bridger G, DiPersio J. Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors. Blood. 106: 5224-5224. DOI: 10.1182/Blood.V106.11.5224.5224 |
0.474 |
|
| 2005 |
Gai BQ, Holt MS, Nervi B, Rettig MP, Ritchey JK, Bridger G, DiPersio JF. Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model. Blood. 106: 5217-5217. DOI: 10.1182/Blood.V106.11.5217.5217 |
0.391 |
|
| 2005 |
Nervi B, Rettig MP, Ritchey JK, Bauer G, Walker J, Hess D, Herrbrich PE, Bonyhadi M, Berenson RJ, Nolta JA, DiPersio JF. Naive and Ex Vivo Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID β 2M Null Mice: A New Xenogeneic Model for GvHD. Blood. 106: 3106-3106. DOI: 10.1182/Blood.V106.11.3106.3106 |
0.433 |
|
| 2005 |
Nervi B, Holt M, Rettig MP, Bridger G, Ley TJ, DiPersio JF. AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy. Blood. 106: 246-246. DOI: 10.1182/Blood.V106.11.246.246 |
0.503 |
|
| 2005 |
Nervi B, Rettig MP, Ritchey JK, Bauer G, Walker J, Herrbrich PE, Meyerrose TE, Bonyhadi M, Nolta JA, DiPersio JF. 810. Ex-Vivo Activation and Genetic Manipulation of Human T Cells Results in Consistent In-Vivo Expansion and Lethal GvHD in a Novel Murine Xenotransplant Model Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.347 |
0.436 |
|
| 2005 |
Rettig MP, Ritchey JK, Nervi B, Bonyhadi ML, DiPersio JF. 709. Comparison of the GVHD-Inducing Potential and GCV Sensitivity of Na|[iuml]|ve and Transduced and Selected CD34-TK-Expressing Murine T Cells after Allogeneic Bone Marrow Transplantation Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.249 |
0.468 |
|
| 2005 |
Nervi B, Rettig M, Ritchey J, Walker J, Bauer G, Herrbrich P, Bonyhadi M, Nolta J, DiPersio J. Suicide gene therapy for human T cell mediated graft versus host disease in a murine xenograft model Biology of Blood and Marrow Transplantation. 11: 45-46. DOI: 10.1016/J.Bbmt.2004.12.135 |
0.328 |
|
| 2004 |
Rettig MP, Ritchey JK, Prior JL, Haug JS, Piwnica-Worms D, DiPersio JF. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. Journal of Immunology (Baltimore, Md. : 1950). 173: 3620-30. PMID 15356106 DOI: 10.4049/Jimmunol.173.6.3620 |
0.44 |
|
| 2004 |
Nervi B, Rettig M, Ritchey J, Walker J, Bauer G, Herrbrich P, Bonyhadi ML, Nolta JA, DiPersio JF. In Vivo Suicide Gene Therapy of Human T Lymphocytes To Prevent Graft Versus Host Disease in a Murine Xenograft Model. Blood. 104: 4979-4979. DOI: 10.1182/Blood.V104.11.4979.4979 |
0.468 |
|
| 2004 |
Nervi B, Rettig M, Ritchey J, Walker J, Bauer G, Herrbrich P, Nolta JA, DiPersio JF. A Murine Xenograft Model for Human T Cell Mediated Graft Versus Host Disease. Blood. 104: 4977-4977. DOI: 10.1182/Blood.V104.11.4977.4977 |
0.444 |
|
| 2004 |
Rettig MP, Ritchey JK, Prior JL, Piwnica-Worms D, Bonyhadi ML, DiPersio JF. In Vivo Bioluminescence Imaging of Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation with Ex Vivo Manipulated Murine T Cells. Blood. 104: 3066-3066. DOI: 10.1182/Blood.V104.11.3066.3066 |
0.47 |
|
| 2004 |
Rettig MP, Ritchey JK, Nervi B, Bonyhadi ML, DiPersio JF. Comparison of the Division Rate and Proliferative Capacity of Naive and Ex Vivo Activated T Cells after Allogeneic Bone Marrow Transplantation. Blood. 104: 2133-2133. DOI: 10.1182/Blood.V104.11.2133.2133 |
0.415 |
|
| 2004 |
Wandersee NJ, Punzalan RC, Sillah NM, Rettig MP, Kennedy MD, Scott JP, Low PS, Hillery CA. Modulation of Erythrocyte Adhesion by Changes in Cellular Tonicity and Volume. Blood. 104: 1577-1577. DOI: 10.1182/Blood.V104.11.1577.1577 |
0.637 |
|
| 2004 |
Nervi B, Rettig M, Ritchey J, Walker J, Bauer G, Herrbrich P, Nolta JA, DiPersio JF. 259. In Vivo Suicide Gene Therapy of Human T Lymphocytes in a Murine Xenograft Model Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.200 |
0.443 |
|
| 2004 |
Walker JE, Bauer G, Herrbrich P, Hess D, Meyerrose T, Nervi B, Rettig M, Nolta JA, DiPersio JF. 606. The NOD-SCID |[beta]|2M null mouse xenograft model for studying activation, expansion and GvHD potential of gene transduced human t cells in vivo Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.1010 |
0.458 |
|
| 2003 |
Rettig MP, Ritchey JK, Meyerrose TE, Haug JS, DiPersio JF. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 8: 29-41. PMID 12842426 DOI: 10.1016/S1525-0016(03)00142-4 |
0.388 |
|
| 2003 |
Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS. Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood. 101: 4625-7. PMID 12560240 DOI: 10.1182/Blood-2001-12-0329 |
0.596 |
|
| 2002 |
de Jong K, Rettig MP, Low PS, Kuypers FA. Protein kinase C activation induces phosphatidylserine exposure on red blood cells. Biochemistry. 41: 12562-7. PMID 12369848 DOI: 10.1021/Bi025882O |
0.46 |
|
| 2001 |
Rettig MP, Orendorff CJ, Campanella E, Low PS. Effect of pH on the self-association of erythrocyte band 3 in situ. Biochimica Et Biophysica Acta. 1515: 72-81. PMID 11597354 DOI: 10.1016/S0005-2736(01)00397-2 |
0.425 |
|
| 2000 |
Low PS, Zhang D, Bolin JT, Chang S, Andrews D, Yang L, Rettig M. Structure, function, and regulation of erythrocyte band 3 (AE1) Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 126: S63. DOI: 10.1016/S0305-0491(00)80125-X |
0.406 |
|
| 1999 |
Rettig MP, Low PS, Gimm JA, Mohandas N, Wang J, Christian JA. Evaluation of biochemical changes during in vivo erythrocyte senescence in the dog. Blood. 93: 376-84. PMID 9864184 DOI: 10.1182/Blood.V93.1.376.401K41_376_384 |
0.512 |
|
| 1998 |
Christian JA, Wang J, Kiyatkina N, Rettig M, Low PS. How Old Are Dense Red Blood Cells? The Dog's Tale Blood. 92: 2590-2591. DOI: 10.1182/Blood.V92.7.2590.2590_2590_2591 |
0.538 |
|
| Show low-probability matches. |